stoxline Quote Chart Rank Option Currency Glossary
  
Evelo Biosciences, Inc. (EVLO)
0.0005  -0 (-0%)    04-23 16:00
Open: 0.0005
High: 0.0005
Volume: 31
  
Pre. Close: 0.000500000024
Low: 0.0005
Market Cap: 0(M)
Technical analysis
2025-04-23 4:38:46 PM
Short term     
Mid term     
Targets 6-month :  0 1-year :  0
Resists First :  0 Second :  0
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 32.7
52-week High :  0.06 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EVLO ] has closed above bottom band by 50.0%. Bollinger Bands are 99.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 02 Apr 2025
5 Best Microbiome Companies (April 2025) - Securities.io

Wed, 22 Nov 2023
Flagship-Founded Microbiome Company Evelo Biosciences Throws in the Towel - BioSpace

Wed, 22 Nov 2023
Flagship-backed microbiome biotech Evelo to shut down - BioPharma Dive

Tue, 18 Jul 2023
Hedge Fund and Insider Trading News: Elliott Investment Management, Cerberus Capital Management, Astaris Capital Management, Discovery Capital Management, Evelo Biosciences, Inc. (EVLO), and More - Insider Monkey

Fri, 16 Jun 2023
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com

Fri, 16 Jun 2023
Evelo Biosciences (EVLO) Stock Soared 331% on a Patent Award - AskTraders.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 19 (M)
Shares Float 17 (M)
Held by Insiders 0.1 (%)
Held by Institutions 12.8 (%)
Shares Short 197 (K)
Shares Short P.Month 156 (K)
Stock Financials
EPS -15.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.42
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -83.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -74 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android